Today: 20 May 2026
Target’s Turnaround Finally Has Numbers Wall Street Can’t Ignore
20 May 2026
2 mins read

Target’s Turnaround Finally Has Numbers Wall Street Can’t Ignore

Minneapolis, May 20, 2026, 06:10 CDT

Target raised its annual sales forecast on Wednesday after stronger-than-expected first-quarter results, an early test passed for new Chief Executive Michael Fiddelke’s effort to pull the retailer out of a long sales slump. The company now expects net sales growth of about 4% this year, two percentage points above its prior range.

It matters now because the gain breaks a weak run. Target had been under pressure after three straight years of declining revenue, with shoppers shifting to lower-price rivals and the chain losing some of the style edge that once made it stand out. Reuters reported the guidance increase was Target’s first upward sales revision in two years.

Fiddelke, who took over from Brian Cornell in February, has put money behind the reset. Target in March outlined an incremental $2 billion investment for 2026, including more store payroll and training, new floor plans, better displays, technology spending and roughly $5 billion in capital investment.

Net sales rose 6.7% to $25.44 billion in the quarter ended May 2. Comparable sales — sales from stores and digital channels open at least a year — rose 5.6%, helped by a 4.4% increase in traffic. Digital comparable sales climbed 8.9%, led by growth of more than 27% in same-day delivery powered by Target Circle 360.

Profit was messier, partly because last year’s quarter included legal settlement gains. Target earned $781 million, or $1.71 a share, down from $1.04 billion, or $2.27 a share, a year earlier. Adjusted earnings were also $1.71 a share, above analysts’ expected $1.47, while sales beat the $24.7 billion expected by FactSet, the Associated Press reported.

Fiddelke said the results offered “encouraging early signs” that Target’s clarified strategy was resonating with shoppers, but he did not present the quarter as a fix. On a media call, he said Target was still keeping “a cautious outlook,” citing work left to do and an uncertain economy. Target Corporation

The gains were broad. Target said sales rose in all six of its core merchandising categories, and non-merchandise sales, including advertising, memberships and its marketplace, rose nearly 25%. Axios reported that executives pointed to demand for limited-edition partnerships, toys, beauty, wellness and baby products; Chief Merchandising Officer Cara Sylvester said guests were responding to “newness.” Axios

The strategy also has a blunt competitive purpose. Reuters reported Target cut prices on about 3,000 items in March, including toys, pantry staples, packaged foods and apparel, as it sought to narrow the gap with Walmart and Amazon on value while keeping its own pitch around style and design. Walmart reports quarterly results on Thursday.

Morningstar analyst Brett Husslein put the problem plainly: Target sits in “a middle ground of retail” — neither the cheapest nor the default destination for one category. That is the hole Fiddelke is trying to close with sharper merchandising, better-stocked shelves and a more interesting store visit. Reuters

Target shares traded at $127.24 before the market opened, up $4.04 from the previous close, after a strong run earlier this year.

But the cleaner sales print does not remove the risks. Target said gross margin improved, helped by supply-chain productivity and lower markdowns, but higher product costs weighed on the quarter. The company also said selling, general and administrative expense rose because of higher compensation costs, more hours and training for field teams, capital project spending and marketing.

The company expects full-year earnings per share near the high end of its prior $7.50 to $8.50 range. That gives Target some room, but not much. The next few quarters will show whether the first quarter was a rebound from weak comparisons or the start of steadier growth.

Stock Market Today

  • U.S. Stock Market Closed on Memorial Day, Bond Market Early Closure Ahead
    May 20, 2026, 10:04 AM EDT. The U.S. stock market will be closed on Memorial Day, Monday, May 25, with the New York Stock Exchange and Nasdaq resuming normal hours on Tuesday. The U.S. bond market will close early at 2 p.m. EDT on Friday, May 22, and remain closed Monday. Over-the-counter trading will also be closed on Memorial Day. Internationally, the London Stock Exchange is closed for the Spring Bank holiday, while the Hong Kong and Tokyo exchanges remain open. This holiday pause impacts traders planning activity around the holiday weekend, as major U.S. financial markets observe federal and regional holidays.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested
Previous Story

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

Meta kicks off 4 a.m. layoff emails as AI drive leads to 8,000 job cuts
Next Story

Meta kicks off 4 a.m. layoff emails as AI drive leads to 8,000 job cuts

Go toTop